Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CEST

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | [email protected]

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | [email protected]
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
08:47p BASF : Dicamba damage is back -- and possibly worse than before
08:44p GHANA OIL : GOIL donates 100 hospital beds to GHS in Western region
08:43p EMERSON ELECTRIC : U.S. Patents Awarded to Inventors in Missouri (June 24)
08:43p FRESENIUS MEDICAL CARE : U.S. Patents Awarded to Inventors in Oklahoma (June 24)
08:43p COLLEGIUM PHARMACEUTICAL : U.S. Patents Awarded to Inventors in Rhode Island (June 24)
08:43p LOCKHEED MARTIN : Federal Contracts Awarded to Companies in Georgia (June 24)
08:43p AUSTAL : Federal Contracts Awarded to Companies in Alabama (June 24)
08:43p GENERAL ELECTRIC : Federal Contracts Awarded by Federal Agencies in Maryland (June 24)
08:42p ENTEGRIS : U.S. Patents Awarded to Inventors in Arizona (June 24)
08:42p COLLEGIUM PHARMACEUTICAL : U.S. Patents Awarded to Inventors in Connecticut (June 24)
Latest news
Advertisement
Hot News 
18.96%IMAGINATION TECHNOLOGIES : U.K. Chip Designer Puts Itself on Block -- WSJ
-5.33%GLOBAL LOGISTIC PROPERTIES : Says It Remains in Talks With Shortlisted Bidders
-12.28%BlackBerry misses sales forecasts, shares tumble
-1.23%Harley-Davidson Discussing Purchase of Italian Rival Ducati From VW
1.40%BOEING : Is Top Seller at Paris Air Show -- WSJ
Most Read News
06/23 WAL MART STORES : Wichita police hosting free bike safety clinic on Saturday
06/23 Europe faces Herculean challenge to develop new fighter jet
06/23 VW EX-MANAGER SHOULD STAY IN GERMANY : lawyer in Bild
09:09a Even with Whole Foods, Amazon would need many more warehouses to reshape grocery delivery
06/23 UNITED TECHNOLOGIES CORPORATION : Khang & Khang LLP Announces Securities Class Action Lawsuit against United Technologies Corporation and Reminds Investors with Losses to Contact the Firm
Most recommended articles
01:37p RAYTHEON : CEO of Raytheon's Forcepoint eyes IPO - Boersen-Zeitung
12:07p Volkswagen's Slovak union says close to wage deal to end strike
09:09a Even with Whole Foods, Amazon would need many more warehouses to reshape grocery delivery
08:15aDJFIAT CHRYSLER'S GREEN AUTOS HAVE A PROBLEM : They're Not for Sale
07:15aDJALPHABET : Google's 'Trust Us' Approach Doesn't Satisfy Pay Gap Skeptics